Featured

Status

Health Topics

Any Category
Diseases
Neoplasms
Neoplasms by Histologic Type
Clear Filters

Search Clinical Trials

55 Results
Recruiting
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer
Participants will be randomized 1:1 to either total Neoadjuvant chemotherapy with with FLOT-TNT ( all 4 cycles of chemotherapy before surgery) or standard of care FLOT-POP ( 2 cycles of …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Study Design: The study will be a two-arm, randomized non-comparative Phase Ib/IIa study of induction dual immunotherapy with durvalumab/tremelimumab OR platinum chemotherapy (cisplatin or carboplatin) and pemetrexed chemotherapy plus dual …
Baylor Role: Lead Sponsor
Recruiting
National Liver Cancer Screening Trial
The TRACER phase IV biomarker study is a randomized trial comparing ultrasound-based screening versus a biomarker-based strategy in patients with cirrhosis. In brief, 5500 patients with cirrhosis from any etiology …
Baylor Role: Collaborator
Recruiting
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
This is a Phase II trial of NEOADJUVANT FOLFIRINOX CHEMOTHERAPY WITH PEMBROLIZUMAB followed by SURGERY and Adjuvant PEMBROLIZUMAB for Patients with LOCALIZED, RESECTABLE Adenocarcinoma of the pancreas. Investigators hypothesize that …
Baylor Role: Lead Sponsor
Recruiting
HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma
PBTC-059 is a multicenter, Phase I and Surgical study of the treatment HER2-specific CAR T cells for patients with refractory or recurrent ependymoma. Phase I The primary objectives of the …
Baylor Role: Collaborator
Completed
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
This is a single arm (non-randomized) first-in-man pilot study to evaluate the safety and feasibility of delivering a dendritic cell vaccine in nine to twenty-four (n=9-24) adult patients diagnosed with …
Baylor Role: Collaborator
Recruiting
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Approximately 118-27 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (approximately 12 tablespoons) is collected from patients to grow the T cells …
Baylor Role: Lead Sponsor
Recruiting
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Treatment with CAdVEC: On the first day of your treatment, participants will receive an injection of CAdVEC into your tumor. A blood sample will be obtained from the participant before …
Baylor Role: Lead Sponsor
Recruiting
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
The primary objective of this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with pancreatic adenocarcinoma lysate …
Baylor Role: Lead Sponsor
Recruiting
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
The SentiNot 2.0 protocol aims to elucidate the effectivity and accuracy of the delayed sentinel lymph node dissection concept (dSLND) when upfront SLND is considered unnecessary, such as in the …
Baylor Role: Collaborator